Otsuka Holdings President and CEO Tatsuo Higuchi on August 2 expressed his enthusiasm about the planned buyout of Jnana Therapeutics announced the previous day, explaining that the significance of the deal lies in the acquisition of its drug discovery technology.…
To read the full story
Related Article
- Otsuka Kicks Off Global PIII of Phenylketonuria Drug
December 22, 2025
- Otsuka Wraps Up Buyout of Jnana Therapeutics
September 25, 2024
- Otsuka Picks Up Jnana Therapeutics for US$800 Million
August 2, 2024
BUSINESS
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- Sumitomo Pharma Eyes Global Position as Adjuvant Supplier
August 24, 2026
- Oncolys’ Oncolytic Virus Telomelysin Hits Japan Market
August 24, 2026
- Sobi’s Still’s Disease Drug Kineret Now Available in Japan
August 24, 2026
- MSD Files Welireg-Keytruda Combo in Japan for Adjuvant RCC
August 24, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





